Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 11Neoplasms 4Neoplasm Metastasis 2Leiomyosarcoma 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma 1Lung Neoplasms 1Liposarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Temozolomide 405Radiotherapy 202Bevacizumab 157Radiation 80Magnetic Resonance Spectroscopy 77Lomustine 49Surgical Procedures, Operative 45Carmustine 41pembrolizumab 40Irinotecan 38Nivolumab 32Specimen Handling 28Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Drug Therapy 23Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15Blood Specimen Collection 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13Ipilimumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × olaratumab × Clear all
NCT00895180 2017-12-27

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
80 enrolled 15 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡